You have access
Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer
DIMITRA STEFANOU, STEFANIA KOKKALI, ELLI-SOPHIA TRIPODAKI, MARIA DRIZOU, ELPIDA MAGOU, DIMOSTHENIS ZYLIS, MARIA PREVEZANOU, MATTHAIOS KAPIRIS, DESPOINA NASI, ANNA NTOKOU, MARY DEDE and ALEXANDROS ARDAVANIS
Anticancer Research November 2018, 38 (11) 6565-6569; DOI: https://doi.org/10.21873/anticanres.13023